Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116415 · ClinicalTrials.gov registry record · NA
DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
A NA study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
NCT00116415 is a NA study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 65 participants.
The verdict
NCT00116415, a NA study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (EFV), didanosine (ddI)-EC and lamivudine (3TC) leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability.
Interventions
- DRUG efavirenz; didanosine EC; lamivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2002-03 |
| Est. Completion | 2004-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116415
The ClinicalTrials.gov registry entry for NCT00116415 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which efavirenz; didanosine EC; lamivudine is the first listed.
NCT00116415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116415 about?
NCT00116415 is a clinical study titled "DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy". The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (EFV), didanosine (ddI)-EC and lamivudine (3TC) leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability.
What is the current status of trial NCT00116415?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2002-03. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00116415?
The interventions under investigation include: efavirenz; didanosine EC; lamivudine (DRUG).
Who is sponsoring clinical trial NCT00116415?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.